Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R
نویسندگان
چکیده
منابع مشابه
Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic stem cell disorders with variable clinical outcome. The International Prognostic Scoring System (IPSS) categorizes untreated MDS patients into one of four risk groups (low, intermediate [Int]-1, Int-2 and high) based on the percentage of bone marrow blasts, presence of cytogenetic abnormalities and number of cytopenias. ...
متن کامل[Revised international prognostic scoring system (IPSS-R) for myelodysplastic syndromes].
Peter L. Greenberg, Heinz Tuechler, Julie Schanz, Guillermo Sanz, Guillermo GarciaManero, Francesc Solé, John M. Bennett, David Bowen, Pierre Fenaux, Francois Dreyfus, Hagop Kantarjian, Andrea Kuendgen, Alessandro Levis, Luca Malcovati, Mario Cazzola, Jaroslav Cermak, Christa Fonatsch, Michelle M. Le Beau, Marilyn L. Slovak, Otto Krieger, Michael Luebbert, Jaroslaw Maciejewski, Silvia M.M. Maga...
متن کاملPrognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic Syndrome
Chromosomal translocations are rare in myelodysplastic syndrome (MDS) and their impact on overall survival (OS) and response to hypomethylating agents (HMA) is unknown. The prognostic impact of the revised International Prognostic Scoring System (IPSS-R) and for chromosomal translocations was assessed in 751 patients from the Korea MDS Registry. IPSS-R effectively discriminated patients accordi...
متن کاملCan the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?
Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS? The " classical " International Prognostic Scoring System (IPSS), based on cytogenetics, marrow blast percentage, and number of cytopenias, has played a major role in prognosis assessment in myelodysplastic syndromes (MDS). 1 The recently published revised IPSS (...
متن کاملPredictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R.
Approximately one-third of patients with myelodysplastic syndrome (MDS) receiving allogeneic hematopoietic stem cell transplantation (HSCT) are cured by this treatment. Treatment failure may be due to transplant complications or relapse. To identify predictive factors for transplantation outcome, we studied 519 patients with MDS or oligoblastic acute myeloid leukemia (AML, <30% marrow blasts) w...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: American Journal of Hematology
سال: 2018
ISSN: 0361-8609
DOI: 10.1002/ajh.25234